Company intelligence / Profile preview

Leysen

Amsterdam, North Holland, Netherlandsleysen.eu ↗

Ownership: Private
Development stage: Other

Overview

Leyden Labs is developing intranasally administered monoclonal antibodies designed to provide immediate and broad protection against respiratory viruses by targeting them at their point of entry—the nasal mucosa. Their lead program, PanFlu™, leverages an exclusive license for CR9114, a broadly-neutralizing anti-influenza antibody. Early clinical results are ongoing; no published late-stage data yet.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyAntibody (broadly neutralizing)Intranasal delivery therapy
Industry: Biotech

Partnerships

Janssen Pharmaceuticals / Johnson & Johnson – exclusive license for CR9114 monoclonal antibody technology.Device/formulation partners for intranasal delivery systems.European Investment Bank financing partnership.

Beyond the preview

Go deeper on Leysen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leysen.

Explore the full profile